Cargando…
MR-proADM as Prognostic Factor of Outcome in COVID-19 Patients
Background: Serum mid-regional proadrenomedullin (MR-proADM) has emerged as a marker of organ failure (mainly lungs and kidneys) and poor prognosis in patients admitted to intensive care (IC); some reports also suggest it and other markers, such as Krebs von den Lungen-6 (KL-6) and interleukin-6 (IL...
Autores principales: | Cameli, Paolo, Pordon, Elena, d’Alessandro, Miriana, Marzi, Maria Laura, Galasso, Lucrezia, Biuzzi, Cesare, Bergantini, Laura, Bargagli, Elena, Scolletta, Sabino, Franchi, Federico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296224/ https://www.ncbi.nlm.nih.gov/pubmed/37371775 http://dx.doi.org/10.3390/biomedicines11061680 |
Ejemplares similares
-
MR-proADM as prognostic factor of outcome in COVID-19 patients
por: Sozio, Emanuela, et al.
Publicado: (2021) -
Dataset of the associations of aldosterone to renin ratio with MR-proANP and MR-proADM
por: Then, Cornelia, et al.
Publicado: (2016) -
MR-proADM and MR-proANP levels in patients with acute pulmonary embolism
por: Öner, Önsel, et al.
Publicado: (2020) -
The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study
por: Cameli, Paolo, et al.
Publicado: (2022) -
Mid-Regional Pro-Adrenomedullin (MR-proADM) as a Biomarker for Sepsis and Septic Shock: Narrative Review
por: Önal, Uğur, et al.
Publicado: (2018)